Health

Photo

Pharma CEOs see risk-averse climate in U.S.

NEW YORK (Reuters) - Pharmaceutical companies see U.S. regulators applying a tougher standard to some new medicines by looking for evidence they are better than drugs already on the market, officials told Reuters this week.

Continue Reading

Democrats to benefit some in U.S. health sector

NEW YORK (Reuters) - While Republicans vying for the U.S. presidency warn about Democratic plans for a "government takeover of healthcare," many companies in the sector see opportunities should a Democrat win.

Momentum builds for biogenerics, execs say

NEW YORK (Reuters) - Despite the failure by U.S. legislators to create a path this year for generic versions of biotech drugs, companies that have invested in the products say such legislation could pass in 2008 and yield generic biologics early in the next decade.

CVS, Medco paths diverge on retailing

NEW YORK (Reuters) - Shares of CVS Caremark Corp have soared 35 percent this year, but you might excuse investors for wishing their money had been elsewhere in 2007.

Novo sees advantages vs Byetta LAR

NEW YORK (Reuters) - Novo Nordisk A/S said on Thursday it believes its experimental type 2 diabetes treatment will be as effective as the Eli Lilly and Co drug expected to be its main rival and may have advantages that will win over patients.

Millennium keeps cool head amid acquisition heat

BOSTON (Reuters) - Biotechnology company Millennium Pharmaceuticals Inc said on Thursday that it won't be as aggressive as some of its rivals when it comes to bidding for experimental new drugs. | Video

Baxter capable of $1 bln in deals/yr

NEW YORK (Reuters) - Baxter International Inc has the capacity to make acquisitions worth $1 billion every year using its own cash flow, its chief executive told the Reuters Health Summit in New York.

Novo sees dimmed prospects for inhaled insulin

NEW YORK (Reuters) - Novo Nordisk A/S sees a limited market for inhaled insulin, but the company is forging ahead with its experimental product to ensure it can offer a complete package of diabetes medicines, a top executive said on Thursday. | Video

Teva sees U.S. generic share above 30 percent

NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd could see its U.S. generic-drug market share swell to more than 30 percent in the next five years, its North American chief said on Thursday. | Video

Personalized medicine slowly taking shape

NEW YORK (Reuters) - Personalized medicine -- tailoring treatments to an individual's genetic profile -- has been one of the main dreams of the gene revolution, but putting it into practice is proving tough.

Millennium CEO very optimistic on Velcade growth

NEW YORK (Reuters) - Millennium Pharmaceuticals Inc Chief Executive Deborah Dunsire on Thursday said the company is upbeat on 2008 growth prospects for its Velcade cancer drug as it eyes approval as a first-line treatment for multiple myeloma. | Video

Speakers

Reporter's Notebook

» More from Summits Blogs

Upcoming Summits

Summit Date Category
Islamic Banking and Finance Feb 15 - 18 Country Summits
Travel and Leisure Feb 22 - 24 Hotels/Casinos
Private Equity and Hedge Funds Mar 1 - 3 Financial Services/Exchanges
Global Mining and Steel Mar 8 - 10 Mining
Food and Agriculture Mar 15 - 18 Mining
Canadian Oil Sands Mar 22 - 23 Energy
Funds Mar 23 - 24 Financial Services/Exchanges
Global Exchanges and Trading Mar 29 - 31 Financial Services / Exchanges
Financial Regulation Apr 26 - 29 Financial Services / Exchanges
» Download Summit Calendar